Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Telazorlimab

            Therapeutic Area: Dermatology Product Name: ISB 830

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 03, 2021


            The two highest doses of telazorlimab, 300 mg and 600 mg administered every two weeks, were statistically superior to placebo. Telazorlimab was well-tolerated during the study to date.